SKIN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SKIN is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below key resistance with a bearish moving-average structure, no recent news catalyst, no strong proprietary buy signal, and analyst sentiment remains mixed-to-cautious despite one Buy rating. Options activity shows extremely elevated speculative interest, but that does not outweigh the weak technical setup and lack of fundamental momentum. My direct view: do not buy now.
Current pre-market price is 0.6416, sitting below the pivot at 0.69 and above the first support at 0.602, which means the stock is in a weak short-term range. MACD histogram is positive and expanding, which is a mild near-term improvement, but RSI_6 at 42.854 is still neutral and not signaling strong momentum. The moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, confirming the broader trend is still downward. The near-term pattern data suggests limited upside with a 40% chance of -0.96% next day, -1.9% next week, and only 0.75% next month. Overall, the technical setup is weak and does not support an immediate long-term entry.
Hedge funds are reportedly buying, with a very large increase in buying amount over the last quarter. The MACD histogram is improving, which may hint at short-term stabilization. Analyst Roth Capital still maintains a Buy rating, and TD Cowen noted FY26 EBITDA guidance implies upside versus Street expectations. Consumable sales are also expected to hold up better than machine placements.
No news in the recent week means there is no fresh catalyst to drive momentum. The stock faces competitive pressure, especially at the low end of the market where cheaper knock-off or scaled-down alternatives exist. Canaccord and TD Cowen both lowered price targets, and Canaccord kept only a Hold rating due to macro uncertainty and pressure on machine placements. The technical trend remains bearish, and the stock is below the pivot level.
Financial snapshot data was not available because of an error, so the latest quarter financials cannot be fully assessed here. From the analyst notes, Q1 results were significant enough to trigger a model update, and the company continues to face pressure on new machine placements due to macro uncertainty and distributor ordering softness. TD Cowen also noted revenue was down in Q4 but still beat expectations, and FY26 EBITDA guidance suggests some upside versus consensus. Overall, the latest available financial commentary points to uneven growth: consumable sales appear more resilient, while core machine placements remain pressured.
Analyst sentiment is mixed and leaning cautious. Roth Capital lowered its target to $2 from $2.50 but kept a Buy rating on 2026-05-20, citing competitive pressure. Canaccord cut its target to $1 from $1.50 and kept Hold on 2026-05-01, pointing to continued pressure on machine placements. TD Cowen lowered its target to $1.50 from $1.65 and kept Hold on 2026-03-16, while acknowledging Q4 revenue beat expectations and FY26 EBITDA upside. Wall Street’s view is therefore split: there is still some upside belief, but the dominant tone is caution around execution and demand conditions.
